

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA Advisory No. 2015 - 022

SUBJECT: PUBLIC HEALTH WARNING AGAINST THE USE OF THE FOLLOWING UNREGISTERED DRUG PRODUCTS:

- 1. DI WANG SHEN DAN 2800 MG CAPSULE
- 2. <u>BLUMAX HERBAL MALE SEXUAL ENHANCER</u>
 <u>CAPSULE</u>
- 3. LURONGXIEBAO 5000 MG CAPSULE

The Food and Drug Administration advises the public against the use of the following unregistered drug products:



DI WANG SHEN DAN 2800 MG CAPSULE

Manufactured by Biological Technology Co., Ltd. – Lhasa; **Site:** The Xizang Middle Road 89, West



BLUMAX HERBAL MALE SEXUAL ENHANCER CAPSULE

Manufactured by Laycock Pharmaceutical Inc. – United Kingdom



LURONGXIEBAO 5000 MG CAPSULE

Manufactured by Hong Kong Tai He Tang Biology

Table 1.Unregistered Drug Products







The abovementioned drug products pose potential danger or injury to the consuming public and the importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009.

In the interest of protecting public health and safety, and pursuant to Section 12 of R.A. No. 9711, the field Food and Drug Regulation Officers of this Office are hereby ordered to seize the aforementioned unregistered drug products found in the market.

All establishments and outlets are hereby warned against selling and/or dispensing the above identified products. Anyone found selling the said products will be penalized.

Likewise, all local government units and law enforcement agencies are requested to ensure that these products are not sold or offered for sale in their localities or area of jurisdiction.

All consumers are advised to purchase their medications only from FDA-licensed establishments. Please note that in addition to inspection of establishments, product evaluation, registration and testing are measures that the government undertakes to ensure the quality, safety and efficacy of health products. Please look for the FDA Registration number on the product label. Moreover, please be reminded that drug products registered with FDA Philippines bear in their labels information in English and/or in Filipino for all consumers to understand.

For more information and inquiries, please email us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly email us via report@fda.gov.ph or you may call the telephone number (02)807-8275. For any suspected adverse drug reaction (ADR), please email us via adr@fda.gov.ph.

ATTY. NICOLAS/B. LUTERO III, CESO III OIC-Director IV, Food and Drug Administration

20150417133508